You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):創新藥“TRD205(AT2R拮抗劑)”已向FDA提交IND申請並獲受理
格隆匯 09-25 06:16

格隆匯9月25日丨中國生物製藥(01177.HK)發佈公吿,集團自主研發的“TRD205(AT2R拮抗劑)”已向美國食品藥品監督管理局(FDA)提交試驗用新藥(IND)申請並獲得受理。 

根據披露,TRD205為血管緊張素II型2受體(AT2R)的新型拮抗劑,擬開發用於治療神經病理性疼痛。神經病理性疼痛是十分常見的一類慢性疼痛,臨牀表現複雜多樣,多數病程超過3個月。患者疼痛特徵不全相同,以灼燒或火燒樣疼痛、電擊樣痛、針刺樣痛、撕裂樣痛較多見。神經痛嚴重影響患者的生活質量,給患者帶來無法忍受的痛苦,研究表明,普通人羣中神經病理性疼痛的發病率高達8%。目前臨牀藥物以阿片類和靶向離子門控通道藥物為主,僅能使四分之一患者獲益。AT2R表達於外周╱皮膚巨噬細胞(MΦs),其啟動是神經損傷部位痛覺敏化的關鍵觸發因素,MΦs中AT2R的啟動觸發活性氧╱氮的產生,從而引起背根神經節(DRG)感覺神經元鈣內流,誘導疼痛超敏反應。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account